The Institute for Clinical and Economic Review (ICER) on Monday announced its plans to analyze the comparative clinical effectiveness and value of Novartis’ canakinumab to reduce cardiovascular risk in patients diagnosed with atherosclerosis.
ICER in a press release said the report will be reviewed during a January 2019 Midwest Comparative Effectiveness Public Advisory Council meeting.
According to the press release, the U.S. Food and Drug Administration approved the treatment in 2009 for rare inflammatory disorders, but is now under review for a new indication in atherosclerosis.
An open input period for the upcoming report kicked off Monday. The deadline from stakeholder input is 5 p.m. EST July 5.